<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>NeLM - Nutrition and Metabolism via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'NeLM - Nutrition and Metabolism' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=NeLM+-+Nutrition+and+Metabolism&t=NeLM+-+Nutrition+and+Metabolism&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 28 Mar 2010 14:48:04 +0100</lastBuildDate>
        <item>
            <title>Nutritional support for acute kidney injury</title>
            <link>http://www.medworm.com/index.php?rid=3210334&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FEvidence%2FDisease-Focused-Reviews%2FNutritional-support-for-acute-kidney-injury%2F</link>
            <description>Source: Cochrane Library
Area: Evidence &gt; Disease Focused Reviews
 Background 
  Treatment for acute kidney Injury (AKI) primarily relies on treating the underlying cause and maintaining the patient until kidney function has recovered. Enteral and parenteral nutrition are commonly used to treat nutritional disorders in AKI patients, however their efficacy in treating AKI are still debated. 
 &amp;nbsp; 
  Objectives 
  To evaluate the effectiveness and safety of nutritional support for patients with AKI. 
 &amp;nbsp; 
  Search strategy 
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Chinese Biomedical Disc, VIP and China National Knowledge Infrastructure (CNKI). 
 &amp;nbsp; 
  Selection criteria 
  All randomised controlled trials (RCTs) reported for AKI ...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3210334</comments>
            <pubDate>Wed, 27 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3210334</guid>        </item>
        <item>
            <title>Does marine omega-3 fatty acid intake protect against cell aging?</title>
            <link>http://www.medworm.com/index.php?rid=3187425&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2010---January%2F20%2FDoes-marine-omega-3-fatty-acid-intake-protect-against-cell-aging%2F</link>
            <description>Source: JAMA
Area: News
 A study of patients with stable coronary artery disease over a five year period found that baseline blood level of marine omega-3 fatty acids was associated with the degree of leucocyte telomere shortening - a potential marker of biological aging. 
 &amp;nbsp; 
 Telomeres are repeated DNA sequences on the end of chromosomes that appear to be protective; they shorten with each cell division, and their length appears to correlate with biological age. Studies have shown an association between short telomeres and cardiovascular morbidity and mortality, and a high intake of omega-3 fatty acids is known to be protective against adverse cardiovascular events. The authors of this study used data from an existing epidemiological study to determine whether an association existed...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3187425</comments>
            <pubDate>Wed, 20 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3187425</guid>        </item>
        <item>
            <title>Risk of sarcopenia with sorafenib in patients with advanced renal cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3187424&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2010---January%2F20%2FRisk-of-sarcopenia-with-sorafenib-in-patients-with-advanced-renal-cell-carcinoma-%2F</link>
            <description>Source: JCO
Area: News
 There is limited research on the isolated effects of specific antineoplastic therapies on progression of cancer-associated advanced skeletal muscle wasting (sarcopenia). In this sub-analysis of the phase III TARGET study (see link below for details of study), sorafenib was selected because of its reported association with weight loss. 
 &amp;nbsp; 
 Observations were made on 80 patients with refractory metastatic renal cell cancer (RCC) who received sorafenib 400 mg twice daily or placebo. Computed tomography (CT) image analysis, which has high precision and specificity for evaluation of specific muscles and adipose tissues, was used to define change in total skeletal muscle and adipose tissue. 
 &amp;nbsp; 
 The following results were noted: .&amp;nbsp;At inclusion, 51% of pat...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3187424</comments>
            <pubDate>Wed, 20 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3187424</guid>        </item>
        <item>
            <title>NICE consults on draft scope for public health guidance on preventing obesity</title>
            <link>http://www.medworm.com/index.php?rid=3181126&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2010---January%2F182%2FNICE-consults-on-draft-scope-for-public-health-guidance-on-preventing-obesity-%2F</link>
            <description>Source: NICE
Area: News
 NICE is developing public health guidance on preventing obesity using a 'whole-system' approach at local and community level.&amp;nbsp; The draft scope has been issued for consultation; please see the link below for details.&amp;nbsp; (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3181126</comments>
            <pubDate>Mon, 18 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3181126</guid>        </item>
        <item>
            <title>Diagnosis and management of vitamin D deficiency</title>
            <link>http://www.medworm.com/index.php?rid=3161821&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2010---January%2F12%2FDiagnosis-and-management-of-vitamin-D-deficiency%2F</link>
            <description>Source: BMJ
Area: News
 The British Medical Journal has featured a review on the diagnosis and management of vitamin D deficiency. The review covers the following topics: 
 &amp;nbsp; 
 .&amp;nbsp;What are the sources of vitamin D? .&amp;nbsp;How can vitamin D deficiency and insufficiency be determined? .&amp;nbsp;Who is at risk of vitamin D insufficiency and deficiency? .&amp;nbsp;How do patients with vitamin D deficiency present? .&amp;nbsp;How should rickets and osteomalacia be treated? .&amp;nbsp;How should moderate vitamin D insufficiency be managed? (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3161821</comments>
            <pubDate>Tue, 12 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3161821</guid>        </item>
        <item>
            <title>European Medicines Agency recommends withdrawal of benfluorex from EU market</title>
            <link>http://www.medworm.com/index.php?rid=3103378&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---December%2F18%2FEuropean-Medicines-Agency-recommends-withdrawal-of-benfluorex-from-EU-market%2F</link>
            <description>Source: EMEA
Area: News
 The European Medicines Agency has recommended the withdrawal of all medicines containing benfluorex in the EU because their risks, particularly the risk of heart valve disease, are greater than their benefits. Benfluorex&amp;nbsp;&amp;nbsp;is&amp;nbsp; a lipid regulating drug used in the treatment of hyperlipidaemias and also as an adjunct in the management of type 2 diabetes mellitus in some EU countries (but not UK). (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3103378</comments>
            <pubDate>Fri, 18 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3103378</guid>        </item>
        <item>
            <title>Health Survey for England 2008: Physical activity and fitness</title>
            <link>http://www.medworm.com/index.php?rid=3103377&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---December%2F18%2FHealth-Survey-for-England-2008-Physical-activity-and-fitness%2F</link>
            <description>Source: NHS Information Centre
Area: News
 The Health Survey for England is a series of annual surveys designed to measure health and health-related behaviours in adults and children living in private households in England. The 2008 Survey focused on physical activity and fitness. Adults and children were asked to recall their physical activity over recent weeks, and objective measures of physical activity and fitness were also obtained. A secondary objective was to examine childhood obesity and other factors affecting health, including fruit and vegetable consumption, drinking and smoking. Trend tables are also available which focus on key changes in core topics and measurements, including estimates of the number, as well as the proportion, of people with a range of health related problem...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3103377</comments>
            <pubDate>Fri, 18 Dec 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3103377</guid>        </item>
        <item>
            <title>NICE consults on evidence used in its guidance on weight management following childbirth</title>
            <link>http://www.medworm.com/index.php?rid=3010637&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---November%2F19%2FNICE-consults-on-evidence-used-in-its-guidance-on-weight-management-following-childbirth%2F</link>
            <description>Source: NICE
Area: News
 NICE has issued for consultation from 19th November-17th December 2009 the evidence used in its guidance on weight management for mothers following childbirth. This evidence will be used by the Public Health Interventions Advisory Committee to develop draft recommendations. (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010637</comments>
            <pubDate>Thu, 19 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3010637</guid>        </item>
        <item>
            <title>Impact of dairy products and dietary calcium on bone-mineral content in children: results of a meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=2983208&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FEvidence%2FDisease-Focused-Reviews%2FImpact-of-dairy-products-and-dietary-calcium-on-bone-mineral-content-in-children-results-of-a-meta-analysis%2F</link>
            <description>Source: DARE
Area: Evidence &gt; Disease Focused Reviews
 CRD Summary: This review evaluated the impact of calcium and dairy product supplementation on bone mineral content in children. It concluded that calcium and dairy products, with or without vitamin D, significantly increase bone mineral content in children with low base-line calcium intakes. Given a number of limitations in the review process, the conclusions of this review should be interpreted with caution.  
 CRD Commentary: The review question was clear and inclusion criteria were specified for participants, outcomes and study design. Relevant databases were searched. Only papers published in English were considered, so it is possible that relevant papers may have been missed. No efforts were made to search for unpublished literatu...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2983208</comments>
            <pubDate>Wed, 11 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2983208</guid>        </item>
        <item>
            <title>The use of pre- pro- and synbiotics in adult intensive care unit patients: systematic review</title>
            <link>http://www.medworm.com/index.php?rid=2914327&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FEvidence%2FDisease-Focused-Reviews%2FThe-use-of-pre--pro--and-synbiotics-in-adult-intensive-care-unit-patients-systematic-review%2F</link>
            <description>Source: DARE
Area: Evidence &gt; Disease Focused Reviews
 CRD Summary: The authors concluded that use of prebiotics, probiotics or synbiotics in adult intensive care unit (ICU) patients did not lead to significant benefit in terms of rates of nosocomial infection or pneumonia, mortality or ICU stay. The conclusion reflected the available evidence, although potential limitations arising from the poor quality and variability of the studies made its reliability uncertain. 
 CRD Commentary: The review addressed a clear question, with sufficiently well-stated inclusion criteria. Several sources were consulted to identify relevant studies, although the search was restricted to publications in English, meaning that language bias was a possibility. Some attempt was made to retrieve unpublished materi...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2914327</comments>
            <pubDate>Wed, 21 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2914327</guid>        </item>
        <item>
            <title>Government to introduce 'Healthier Food Mark'</title>
            <link>http://www.medworm.com/index.php?rid=2896929&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---October%2F15%2FGovernment-to-introduce-Healthier-Food-Mark%2F</link>
            <description>Source: Department of Health (DH)
Area: News
 The Government wants the public sector to lead by example in the delivery of healthier, more sustainable food. It is planning a scheme to encourage and recognise best practice among public sector organisations buying and serving food, under the working title the 'Healthier Food Mark'. The Department of Health, Defra and the FSA are working as part of a cross government group with the food industry, public sector organisations and other stakeholders to create this voluntary scheme, which will be tested as a pre-consultation pilot in 2009-10; then a full consultation will follow in 2010 and the scheme will potentially roll-out in 2011. (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896929</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2896929</guid>        </item>
        <item>
            <title>Acomplia (rimonabant) 20mg film coated tablets - licence suspension</title>
            <link>http://www.medworm.com/index.php?rid=2811122&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FOther-Lib-Updates%2FSPC-Changes%2FAcomplia-rimonabant-20mg-film-coated-tablets---licence-suspension-%2F</link>
            <description>Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates &gt; SPC Changes
 Acomplia (rimonabant) 20mg film coated tablets from Sanofi-aventis has had its licence suspended. (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811122</comments>
            <pubDate>Sat, 19 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2811122</guid>        </item>
        <item>
            <title>Aldurazyme (laronidase) 100 U/ml concentrate for solution for infusion - Revised SPC</title>
            <link>http://www.medworm.com/index.php?rid=2811121&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FOther-Lib-Updates%2FSPC-Changes%2FAldurazyme-laronidase-100-Uml-concentrate-for-solution-for-infusion---Revised-SPC%2F</link>
            <description>Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates &gt; SPC Changes
 Extravasation, cyanosis and tachypnoea have been added&amp;nbsp;to section 4.8 (undesirable effects).&amp;nbsp; (Source: NeLM - Nutrition and Metabolism)</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2811121</comments>
            <pubDate>Sat, 19 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2811121</guid>        </item>
        <item>
            <title>FDA safety review of liver-related adverse events with orlistat (AlliT and XenicalT)</title>
            <link>http://www.medworm.com/index.php?rid=2750196&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---August%2F26%2FFDA-safety-review-of-liver-related-adverse-events-with-orlistat-Alli-and-Xenical%2F</link>
            <description>Source: FDA
Area: News
 The US FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat (POM XenicalTand OTC AlliT). 
 &amp;nbsp; 
 According to the FDA's Adverse Event Reporting System, 32 reports of serious liver injury, including 6 cases of liver failure, were submitted between 1999 and October 2008 in patients using orlistat; 30 of these reports occurred outside the US and 27 cases resulted in hospitalisation. The most commonly reported adverse events were jaundice, weakness and abdominal pain. 
 &amp;nbsp; 
 In addition to the 32 reported cases, the FDA is reviewing other data on suspected cases of liver injury submitted by the manufacturers of orlistat and will communicate its findings once its review is complete. 
 &amp;nbsp; 
 For th...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2750196</comments>
            <pubDate>Tue, 25 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2750196</guid>        </item>
        <item>
            <title>Supply shortage of imiglucerase (Cerezyme®) - updated treatment recommendations</title>
            <link>http://www.medworm.com/index.php?rid=2750197&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---August%2F17%2FSupply-shortage-of-imiglucerase-Cerezyme--updated-treatment-recommendations-%2F</link>
            <description>Source: EMEA
Area: News
 The European Medicines Agency has been informed that the supply shortage of imiglucerase (Cerezyme®) is more severe than previously expected, and the Committee for Medicinal Products for Human Use (CHMP) has therefore agreed to new temporary treatment recommendations.&amp;nbsp; Only patients at greatest need of treatment will receive the drug, albeit at a reduced dose, until the shortage is resolved. 
 &amp;nbsp; 
 Cerezyme is used in the treatment of patients with Gaucher disease, a disease in which patients do not have enough of an enzyme called alglucerase.&amp;nbsp; The updated recommendations during the supply shortage are as follows: 
 &amp;nbsp; 
 .&amp;nbsp;Infants, children and adolescents should receive Cerezyme at a reduced dose or at a reduced infusion frequency. However,...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2750197</comments>
            <pubDate>Sun, 16 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2750197</guid>        </item>
        <item>
            <title>Literature review and recommendations on use of medications with continuous enteral nutrition</title>
            <link>http://www.medworm.com/index.php?rid=2750198&amp;cid=s_38910_28_f&amp;fid=38910&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---August%2F13%2FLiterature-review-and-recommendations-on-use-of-medications-with-continuous-enteral-nutrition%2F</link>
            <description>Source: Am J Health-Syst Pharm
Area: News
 Recommendations for the use of medications with continuous enteral nutrition have been published in the American Journal of Health-System Pharmacy. 
 &amp;nbsp; 
 Forty-six medications commonly given to hospitalised patients were evaluated. Following a literature review, contact with manufacturers and a consensus from clinicians for those medications that lacked specific recommendations from these two sources, the authors collated the data to produce recommendations classified as strong (grade 1) or weak (grade 2). The quality of evidence was classified as high (grade A), moderate (grade B), or low (grade C). 
 &amp;nbsp; 
 Twenty-four medications had recommendations based on available data, and the remaining 22 medications had recommendations based on a ...</description>
            <author>NeLM - Nutrition and Metabolism</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2750198</comments>
            <pubDate>Wed, 12 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2750198</guid>        </item>
    </channel>
</rss>

